Angiotensin converting enzyme inhibitors for reduction of proteinuria in children with steroid-resistant nephrotic syndrome.
about
Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study designTherapeutic approach to FSGS in children.A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis.Congenital Nephrotic Syndrome - Finish Type.Increasing frequency of acute kidney injury amongst children hospitalized with nephrotic syndrome.
P2860
Angiotensin converting enzyme inhibitors for reduction of proteinuria in children with steroid-resistant nephrotic syndrome.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh
1991年學術文章
@zh-hant
name
Angiotensin converting enzyme ...... -resistant nephrotic syndrome.
@en
Angiotensin converting enzyme ...... -resistant nephrotic syndrome.
@nl
type
label
Angiotensin converting enzyme ...... -resistant nephrotic syndrome.
@en
Angiotensin converting enzyme ...... -resistant nephrotic syndrome.
@nl
prefLabel
Angiotensin converting enzyme ...... -resistant nephrotic syndrome.
@en
Angiotensin converting enzyme ...... -resistant nephrotic syndrome.
@nl
P356
P1433
P1476
Angiotensin converting enzyme ...... -resistant nephrotic syndrome.
@en
P2093
B Z Morgenstern
D S Milliner
P2888
P304
P356
10.1007/BF00856646
P577
1991-09-01T00:00:00Z